FONAR Board of Directors Appoints Independent DirectorJuly 02, 2025 4:10 PM EDT | Source: Fonar CorporationMelville, New York--(Newsfile Corp. - July 2, 2025) - FONAR Corporation (NASDAQ: FONR), The Inventor of MR Scanning, today announced that on July 2, 2025, its board of directors appointed Mr. Robert M. Carrino as an independent director of the Company's board of directors. This appointment fills a vacancy on the board left by Ms. Claudette J.V. Chan, who recently retired from her position ...

Raise your hand if you've ever scraped your knee or maybe cut your finger on a sharp object or maybe burned your hand on a hot stove. Most of us, right. Your body does something amazing.It sends in a repair team that lays down a scab to stop the bleeding and then specialized cells digest or remove all of that dead or injured tissue and lay down a scar. Now imagine this. What happens if your heart gets injured.Does it just scab over. Let me tell you a story where healing is more than just bandages. where glo ...

Key Takeaways GE HealthCare unveiled Flyrcado, its FDA-approved PET agent for cardiac imaging, at SNMMI 2025. Flyrcado supports GEHC's growth in precision cardiac care by enabling earlier, more personalized diagnosis. GEHC gained CMS pass-through status and insurer coverage to accelerate Flyrcado's national rollout.GE HealthCare (GEHC) recently unveiled new advancements in precision cardiac care at the 2025 SNMMI annual meeting in New Orleans, with a spotlight on Flyrcado—its FDA-approved Positron Emissio ...

MELBOURNE, Australia and INDIANAPOLIS, June 20, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces it has launched a novel PET1 radiochemistry solution based on 18F-aluminium fluoride (AlF), named AlFluor™. The AlFluor™ platform technology enables flexible radiolabeling of PSMA2 with either AlF or gallium-68 (68Ga). It also has the potential to be used with ligands targeting NETs3 and FAP4, as well as other novel imaging agents under devel ...

Key Takeaways Bayer has filed an NDA with the FDA for gadoquatrane, a low-dose gadolinium MRI contrast agent. Gadoquatrane cuts gadolinium dose by about 60% compared to current macrocyclic GBCAs. QUANTI studies showed gadoquatrane improves image quality with no new safety concerns in adults or children.Bayer (BAYRY) announced that it has submitted a new drug application (“NDA”) to the FDA seeking approval for its investigational low-dose gadolinium-based contrast agent (“GBCA”), gadoquatrane, for use in c ...

Key Takeaways GE HealthCare launched the bkActiv S Series for image-guided, non-surgical urology and pelvic procedures. GEHC's bkActiv S Series offers AI tools, TruSense tech, and single-handed controls for clinician efficiency. GEHC aims to grow recurring revenue through transducer sales, service contracts, and software upgrades.GE HealthCare Technologies Inc. (GEHC) recently expanded its bkPortfolio family of Active Imaging systems with the launch of the bkActiv S Series, a next-generation ultrasound so ...

FORT WORTH, Texas, June 17, 2025 (GLOBE NEWSWIRE) -- Brandon Sisson, CEO of Redacted Optics, today issued the following statement to shareholders following the formal transition of VNUE, Inc. (OTC: VNUE) operations and assets: “It’s hard to put into words the work, sacrifice, and belief it has taken to build this company. What started as a focused mission to innovate the optics space has grown into something far greater—something with the potential to reshape how defense, law enforcement, and sportsmen ope ...

Joint Clinical Study with Massachusetts General Hospital Could Pave the Way for Testing Efficacy of Quantum's Investigational MS drug, Lucid-21-302 TORONTO, June 17, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announces that the first person with multiple sclerosis (MS) has been scanned in a joint study with Massachusetts ...

ProMIS Neurosciences (PMN) FY Conference June 17, 2025 07:00 AM ET Speaker0 Hello everyone and welcome to this latest series of fireside chats here at the Perspectives on Neurology mini conference hosted by H. C. Wainwright. My name is Ram Selvaraju and I'm a Managing Director and Senior Healthcare Equity Research Analyst here within Wainwright's Equity Research Department. I'm joined here today by Neil Warmah, Chief Executive Officer of Promise Neurosciences, a publicly traded biotechnology company focusin ...

Core Insights - SkyWater Technology's Wafer Services revenues experienced a 25% year-over-year decline in Q1 FY25 due to decreased demand from automotive customers, but a strong sequential rebound of 70% to $7.5 million was driven by the launch of the ThermaView platform [2][9] - ThermaView, SkyWater's first internally developed product platform for thermal imaging, is already being deployed by two major U.S. defense contractors, indicating its significance in mission-critical applications [3][9] - The company anticipates that ThermaView will be a key growth driver for Wafer Services through FY25, addressing a projected $9 billion market opportunity by 2027 [4][5] Financial Performance - For Q2 FY25, SkyWater expects Wafer Services revenues to be between $5 million and $6 million, reflecting ongoing demand for ThermaView [4][9] - SkyWater's shares have declined by 40.6% year-to-date, contrasting with the Zacks Electronics – Semiconductors industry's return of 3.9% [8] - The current forward 12-month price-to-sales ratio for SkyWater is 1.17, significantly lower than the industry average of 8X, making it an attractive option for value investors [10] Earnings Estimates - The Zacks Consensus Estimate for SkyWater's 2025 loss is currently at 1 cent per share, which has narrowed by 85.7% over the past 60 days, indicating a year-over-year decline of 116.67% [11] - Earnings estimates for the upcoming quarters show a projected loss of $0.17 for the current quarter, a profit of $0.09 for the next quarter, and a loss of $0.01 for the current year [12] Competitive Landscape - SkyWater faces significant competition from GlobalFoundries, which offers a wide range of process technologies and serves diverse markets, holding advantages in scale and capacity [6] - Tower Semiconductor specializes in analog, RF, and MEMS technologies, targeting high-value niches and offering customizable solutions, which positions it as a strong competitor in complex analog projects [7]